Protecting Our Pharmaceutical Supply Chain from China Act of 2020

United States116th CongressHR-6482House of Representatives
Updated: Jul 13, 2020

Summary

Protecting Our Pharmaceutical Supply Chain from China Act of 2020 This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

Bill texts

Available versions
Introduced (House)View official text

1 version available

All available records shown.

Timeline

Latest companion bill action

S-3635: Protecting Our Pharmaceutical Supply Chain from China Act of 2020

Read twice and referred to the Committee on Finance.

  1. Introduced in House

  2. Referred to the Subcommittee on Health.

    House of Representatives

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  4. Referred to the Subcommittee on Oversight and Investigations.

    House of Representatives

All available records shown.